Skip to main content

Funded Grants

Filter by:
Clear Filters
Filter by:

853 results found

Amyloid beta oligomers: refining the therapeutic target through photolabelling and fractionation

We know that Alzheimer’s disease is caused by the clumping together of misfolded proteins in the brain, specifically two proteins called amyloid beta and tau.


Grant type
Capacity building grants
Area of Research
Neurodegeneration
Competition
Alzheimer Society Research Program (ASRP)
Province
Alberta
Start Date
2024

Novel digital and adaptive marker of word-finding difficulties for early detection of Alzheimer’s disease

Over 64% of older adults without neurocognitive disorders report forgetting the names of objects when speaking.


Grant type
Capacity building grants
Area of Research
Neurodegeneration
Competition
Alzheimer Society Research Program (ASRP)
Province
Québec
Start Date
2024

Understanding addiction through zebrafish: unveiling new solutions

Addiction is a massive issue that spans generations and cultures.


Grant type
Capacity building grants
Area of Research
Mental Health
Competition
Doctoral Personnel Awards for Indigenous Scholars
Province
Alberta
Start Date
2024

A “tipping point” neuron type driving Alzheimer’s Disease progression

Alzheimer’s Disease (AD) is characterized by dysregulation of neurons involved in memory, which is believed to be caused by the production of an agent termed “amyloid beta”.


Grant type
Capacity building grants
Area of Research
Neurodegeneration
Competition
Alzheimer Society Research Program (ASRP)
Province
British Columbia
Start Date
2024

DBS-PPN-AD: A Pilot Clinical Trial Investigating Deep Brain Stimulation of the Pedunculopontine Nucleus for theTreatment of Alzheimer’s Disease

Gamma oscillations (GO) are electrical signals detected in the brain that are essential for memory and cognition.


Grant type
Capacity building grants
Area of Research
Neurodegeneration
Competition
Alzheimer Society Research Program (ASRP)
Province
Ontario
Start Date
2024

Health system implications of novel therapeutics for Alzheimer’s Disease: Supporting capacity planning with real-world evidence

Close to 600,000 Canadians currently live with Alzheimer’s disease and related dementias, but effective therapies are limited and focus on symptom management rather than a cure.


Grant type
Capacity building grants
Area of Research
Neurodegeneration
Competition
Alzheimer Society Research Program (ASRP)
Province
Ontario
Start Date
2024

Targeting the USP19 deubiquitinating enzyme for the treatment of Alzheimer’s disease

Alzheimer’s disease progresses over time due to the spreading of aggregates of tau protein and amyloid protein from unaffected to affected regions of the brain.


Grant type
Capacity building grants
Area of Research
Neurodegeneration
Competition
Alzheimer Society Research Program (ASRP)
Province
Québec
Start Date
2024

Does psilocybin increase synaptic density in the brain in patients with mild cognitive impairment?

Amnestic mild cognitive impairment (aMCI) is viewed as a precursor to Alzheimer’s Disease (AD) for which there are no effective treatments.


Grant type
Capacity building grants
Area of Research
Neurodegeneration
Competition
Alzheimer Society Research Program (ASRP)
Province
Ontario
Start Date
2024

Genes involved in APP-mediated GLUT1 regulation

Alzheimer’s disease is the most common form of dementia.


Grant type
Capacity building grants
Area of Research
Neurodegeneration
Competition
Alzheimer Society Research Program (ASRP)
Province
Québec
Start Date
2024

Targeting the microbiota-gut-brain axis with diet and exercise interventions in individuals with subjective cognitivedecline

Individuals with or at increased risk of Alzheimer’s disease (AD) have an altered community of microbes(microbiome) within the intestinal tract.


Grant type
Capacity building grants
Area of Research
Neurodegeneration
Competition
Alzheimer Society Research Program (ASRP)
Start Date
2024